ADMP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 Sep 2023 @ 03:59):

Stats
今日成交量	119 482
平均成交量	3.11M
市值	7.25M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0764
ATR14	$0.190 (30.44%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Dorbin John W. Jr.	Buy	70 000	Employee Stock Option (right to buy)
2023-10-23	Dorbin John W. Jr.	Buy	0
2023-10-16	Cohen Seth	Buy	151 416	Employee Stock Option (right to buy)
2023-10-16	Cohen Seth	Buy	0
2023-09-15	Versi Ebrahim	Buy	729 200	Common Stock

INSIDER POWER
93.12
Last 88 transactions
Buy: 1 947 813 \| Sell: 1 308 563

音量相关性

長: -0.04 (neutral)

短: -0.22 (neutral)

Signal:(43.501) Neutral

Adamis Pharmaceuticals 相关性

10 最正相关
AGRX	0.964
VLCN	0.956
VRAY	0.949
HAIN	0.947
NDLS	0.944
IONM	0.943
NSTG	0.943
ENSC	0.941
CLPT	0.941
NEXT	0.938

10 最负相关
ADSE	-0.961
NWLI	-0.96
PRSRU	-0.954
EVLV	-0.942
BTWN	-0.934
STCN	-0.932
CCRC	-0.932
ARNA	-0.931
DSEY	-0.931
DMRC	-0.928

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Adamis Pharmaceuticals 相关性 - 货币/商品

0.70
( moderate )

0.66
( moderate )

0.00
( neutral )

0.74
( moderate )

-0.30
( neutral )

-0.62
( weak negative )

Adamis Pharmaceuticals 财务报表

Annual	2022
营收:	$4.76M
毛利润:	$-1.43M (-30.10 %)
EPS:	$-12.24

FY	2022
营收:	$4.76M
毛利润:	$-1.43M (-30.10 %)
EPS:	$-12.24

FY	2021
营收:	$2.21M
毛利润:	$-4.66M (-211.14 %)
EPS:	$-0.320

FY	2020
营收:	$16.53M
毛利润:	$1.63M (9.88 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.